Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma

EAU-EBU Update Series

Volumn 5, Issue 1, 2007, Pages 26-37

  Staehler, Michael ^a   Haseke, Nicolas ^a   Schoeppler, Gita ^a   Stadler, Thomas ^a   Gratzke, Christian ^a   Stief, Christian G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anti angiogenesis; Renal cell carcinoma; Targeted agents; Therapy; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CETUXIMAB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 2; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY G250; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PANITUMUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SORAFENIB; SUENT; SUNITINIB; TEMSIROLIMUS; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BACKACHE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOWNSTREAM PROCESSING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FATIGUE; GENE TARGETING; HAIR DISEASE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY SURGERY; LOW DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; POSTOPERATIVE PERIOD; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 33846681333     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2006.08.004     Document Type: Review

References (68)

1. http://www.seer.cancer.gov/. 2006.
2. Janzen N.K., Kim H.L., Figlin R.A., and Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
3. Negrier S. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol 22 (2004) 1174-1176
4. Pantuck A.J., Belldegrun A.S., and Figlin R.A. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 345 (2001) 1711-1712
5. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
6. Mickisch G.H., Garin A., van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
7. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80 (1997) 1198-1220
8. Figlin R.A. Renal cell carcinoma: management of advanced disease. J Urol 161 (1999) 381-386 discussion 6-7
9. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
10. Atzpodien J., Kirchner H., Jonas U., Bergmann L., Schott H., Heynemann H., et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
11. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
12. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
13. Makino Y., Kanopka A., Wilson W.J., Tanaka H., and Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277 (2002) 32405-32408
14. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
15. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
16. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62 (2002) 2957-2961
17. Davidowitz E.J., Schoenfeld A.R., and Burk R.D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21 (2001) 865-874
18. de Paulsen N., Brychzy A., Fournier M.C., Klausner R.D., Gnarra J.R., Pause A., et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 98 (2001) 1387-1392
19. Gnarra J.R., Lerman M.I., Zbar B., and Linehan W.M. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22 (1995) 3-8
20. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
21. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
22. Knebelmann B., Ananth S., Cohen H.T., and Sukhatme V.P. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58 (1998) 226-231
23. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
24. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57 (1997) 5328-5335
25. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., and Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59 (1999) 3915-3918
26. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
27. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
28. Slaton J.W., Inoue K., Perrotte P., El-Naggar A.K., Swanson D.A., Fidler I.J., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735-743
29. Jacobsen J., Rasmuson T., Grankvist K., and Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163 (2000) 343-347
30. Bukowski R.M., and Bro W.P. Review. Kidney Cancer J 2 (2004) 10-15
31. Brenner W., Farber G., Herget T., Lehr H.A., Hengstler J.G., and Thuroff J.W. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99 (2002) 53-57
32. Bui M.H., Seligson D., Han K.R., Pantuck A.J., Dorey F.J., Huang Y., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
33. Stadler W., and Wilding G. Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol 46 (2003) S41-S47
34. Oosterwijk E., Ruiter D.J., Hoedemaeker P.J., Pauwels E.K., Jonas U., Zwartendijk J., et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38 (1986) 489-494
35. Oosterwijk E., Bander N.H., Divgi C.R., Welt S., Wakka J.C., Finn R.D., et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 11 (1993) 738-750
36. Bleumer I., Knuth A., Oosterwijk E., Hofmann R., Varga Z., Lamers C., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90 (2004) 985-990
37. Bleumer I., Oosterwijk E., Oosterwijk-Wakka J.C., Voller M.C., Melchior S., Warnaar S.O., et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175 (2006) 57-62
38. Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
39. Fishman M., and Antonia S. Specific antitumour vaccine for renal cancer. Lancet 363 (2004) 583-584
40. Gitlitz B.J., Belldegrun A.S., Zisman A., Chao D.H., Pantuck A.J., Hinkel A., et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26 (2003) 412-419
41. Barbuto J.A., Ensina L.F., Neves A.R., Bergami-Santos P., Leite K.R., Marques R., et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 53 (2004) 1111-1118
42. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 (2003) 483-494
43. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 15 (2006) 553-561
44. Staehler M., Rohrmann K., Haseke N., Stief C.G., and Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6 (2005) 835-846
45. Motzer R., Rini B., Michaelson D., Redman B., Hudes G., Wilding G., et al. SU11248, a novel tyrosin kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. Proc Am Assoc Cancer Res 381 (2004) (Abstract 4500)
46. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
47. Rini B.I. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer 4 (2005) 175-180
48. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. Sunitinib Malat (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: actual phase-II results. ECCO. 2005:Abstr. 797.
49. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) (Late breaking Abstract, ASCO 2006). J Clin Oncol 24 (2006) 930s LBA3
50. Ratain M, Flaherty K, Stadler W, O'Dwyer P, Kaye S, Xiong H, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Proc Am Assoc Cancer Res 2004; 23(381):(Abstract 4501). See also oral presentation at www.asco.org/.
51. Escudier B, Szczylik C, Eisen T, Oudard S, Staehler M, Negrier S, et al. Randomized Phase III Trial of The Multi-kinase Inhibitor Sorafenib (BAY 43-9006) in Patients With Advanced RCC. ECCO. 2005:Abstr. 794.
52. Motzer R.J., Bacik J., and Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 10 (2004) 6302S-6303S
53. Patel P.H., Chaganti R.S., and Motzer R.J. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94 (2006) 614-619
54. Staehler M., Haseke N., Schoppler G., Stadler T., Adam C., and Stief C.G. Therapy strategies for advanced renal cell carcinoma. Urologe A 45 (2006) 99-110 quiz 1-2
55. Gollob JA, Moran K, Jones JM, Bael TE, Rathmell WK, B.L. P. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal carcinoma. Eur J Cancer. 2005;3:226-9.
56. Foon K.A., Yang X.D., Weiner L.M., Belldegrun A.S., Figlin R.A., Crawford J., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 (2004) 984-990
57. Rowinsky E.K., Schwartz G.H., Gollob J.A., Thompson J.A., Vogelzang N.J., Figlin R., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22 (2004) 3003-3015
58. Motzer R.J., Amato R., Todd M., Hwu W.J., Cohen R., Baselga J., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21 (2003) 99-101
59. Dancey J.E. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?. J Clin Oncol 22 (2004) 2975-2977
60. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
61. Rawat A., Needle M.N., Miles B., and Amato R.J. Phase II study of CC-5013 in patients with metastatic renal cell cancer. J Clin Oncol 23 (2005) 403s (Abstract 4604)
62. Ebbinghaus S.W., Hussain M., Tannir N.M., Gordon M.S., Dessai A.A., Knichg R.A., et al. A randomized phase 2 study of thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advance renal cell carcinoma. J Clin Oncol 23 (2005) 404s (Abstract 4607)
63. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., and Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
64. Hainsworth J.D., Sosman J.A., Spigel D.R., Patton J.F., Thompson D.S., Sutton V., et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advance renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network phase I/II trial. J Clin Oncol 23 (2005) 388s (Abstract 4542)
65. Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
66. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
67. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
68. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R.A., Kapoor A., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) (Late breaking Abstract, ASCO 2006). J Clin Oncol 24 (2006) 930s LBA4